| Literature DB >> 27919586 |
Roongroj Bhidayasiri1, Pedro J Garcia Ruiz2, Tove Henriksen3.
Abstract
The potential for adverse events is often cited as a barrier to the use of subcutaneous apomorphine therapy (intermittent injections and continuous infusion) in the management of Parkinson's disease. However, with proactive management most adverse effects are manageable if reported and tackled early enough. As such, proper clinician and patient awareness of the potential adverse effects is important to minimize their impact on the overall clinical utility of this efficacious antiparkinsonian agent. In this paper, we review the key local and systemic adverse effects reported during apomorphine titration, initiation and long-term treatment, and discuss practical management strategies.Entities:
Keywords: Adverse events; Apomorphine; Safety; Tolerability
Mesh:
Substances:
Year: 2016 PMID: 27919586 DOI: 10.1016/j.parkreldis.2016.11.017
Source DB: PubMed Journal: Parkinsonism Relat Disord ISSN: 1353-8020 Impact factor: 4.891